Informed Prostate Cancer Patient Support

Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer—A case report October 2024 Frontiers in Medicine 11 DOI: 10.3389/fmed.2024.1462234 Carsten S Kramer ,  Jingjing Zhang ,  Richard P. Baum Authors Authors and Affiliations: 1. Carsten S. Kramer - CURANOSTICUM Wiesbaden-Frankfurt, Germany - Center for Advanced Radiomolecular Precision Oncology 2. Jingjing Zhang - Department of Diagnostic Radiology - Clinical Imaging Research Centre - National University of Singapore 3. Richard P. Baum (corresponding author) - CURANOSTICUM Wiesbaden-Frankfurt - Center for Advanced Radiomolecular Precision Oncology - Email: baumrp@gmail.com - Noted as a shareholder of Benfovir AG and Oxy5 OncoMedical AG (disclosed conflict of interest) Institutional Context: The primary work was conducted at CURANOSTICUM Wiesbaden-Frankfurt, which is a center specializ...

Just Get The Bad Parts - Focal therapy ablation patterns; Summary This systematic review examines outcomes of established focal therapy (FT) techniques (cryotherapy, HIFU, and IRE) for prostate cancer, analyzing 49 unique cohorts from 2008-2024. Key findings: - Strong short-term oncological outcomes: 98% overall survival, 99.3% cancer-specific survival, 98.5% metastasis-free survival - Annual biochemical progression rate: 9.4% - Post-treatment biopsy outcomes: 22.2% clinically significant cancer detection (8.9% in-field, 12.3% out-of-field) - Treatment failure rates: 5% required second FT, 10.5% needed radical therapy, 14.1% composite failure rate - Good functional outcomes: Low-moderate impact on sexual function, minimal impact on urinary function - No significant differences in outcomes between cryotherapy, HIFU, and IRE Evolution of practice: - Increasing focus on treating clinically significant cancers rather than low-risk disease - Shift from hemi-gland to more targeted focal trea...